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Human immunodeficiency virus (HIV), the causative agent of the acquired im-
munodeficiency syndrome (AIDS), infects and replicates within severaltypes ofhuman
cells (1-4) . Although early studies of this retroviral pathogen focused on CD4' T
lymphocytes as the principal target cell, there is increasing evidence that infection
of cells belonging to the monocyte/macrophage (M/M)' lineage plays a crucial role
in the pathogenesis andprogression of this disease (2, 5, 6) . In addition, sinceM/M
may differ from T cells in their intracellular metabolism of drugs and their reaction
to lymphokines, it is important that one consider the effect of antiretroviral ther-
apeutic strategies on cells of the M/M lineage .
Our group has previously shown that 2'3'-dideoxynucleosides (ddN), a family of
compounds lackingan hydroxy group at the 3' position ofthe sugar .noiety, arepotent
in vitro inhibitors ofHIVreplication in bothhumanTlymphocytes andM/M(7-9) .
In addition, severalmembers ofthis family of drugshave been shown to have clinical
activity when administered to patients with severe HIV infection (10-12) . One of
thesecompounds, 3'-azido-2'3'-dideoxythymidine (AZT)prolongs lifeand improves
neurologic abnormalities (10, 12-14) in certain patients withAIDS . TheuseofAZT,
however, is associated with bone marrow suppression and other toxic side effects
(15), particularly in patients with established AIDS, so that a recent focus of investi-
gation has been directed toward developing strategies to overcome this problem . One
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oxythymidine; AZTTP, 3'-azido-2'3'-dideoxythymidine-5'-triphosphate ; dCTP, 2'-deoxycytidine-5'-tri-
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approach currently under investigation is the use of granulocyte-macrophage CSF
(GM-CSF). GM-CSF is a cytokine that stimulates the maturation and differentia-
tion of granulocyte and monocyte bone marrow precursor cells (16-18). In addition,
Hammer et al. (19, 20) have suggested that GM-CSF can inhibit HIV replication
in U937, a CD4+ cell line with certain monocytoid properties. However, Folks et
al. (21) have found that GM-CSF may actually stimulate HIV replication in a sub-
clone of U937.
Because of the interest in using GM-CSF in patients with HIVrelated disease
and the conflicting results obtained in monocytoid cell lines, which may or may not
be reliable biochemical models for normal M/M, we undertook an investigation of
the in vitro effect of GM-CSF on HIV replication in purified human peripheralblood
M/M, both as a single agent and in conjunction with dideoxynucleosides. Our results
show that GM-CSF enhances HIV replication in fresh M/M by several hundred-fold,
and moreover, that infection of such stimulated cells can take place-with lower con-
centrations of virus. In spite of this, the net potency of AZT and related dideoxy-
thymidine analogues in inhibiting HIV infection is markedly increased in the pres-
ence of GM-CSF. This increase in activity appears to result from an enhanced cell
entry ofdrug and production ofphosphorylated (activated) drugs in the face of min-
imal increases in the levels of the competing thymidine triphosphate. These results
may have implications for the design of improved therapeutic strategies for patients
with AIDS and related conditions.
Materials and Methods
Cells.
￿
Monocyte-enriched PMBC were obtained from healthy, HIVnegative donors using
a cell separator (Fenwal C3000; Travenol Inc., Deerfield, IL). The PBMC were then further
enriched for M/M by elutriation as described by Gerrard et al. (22). M/M obtained by elutri-
ation followed by a 5-d culture were >95% nonspecific esterase positive (Technicon Instru-
ments Corp., Tarrytown, NY), and >95% actively phagocytized 0.8-P. latex beads (Sigma
Chemical Co., St. Louis, MO). In addition, they were <1% E-rosette positive, and 50%
OKT4A' (Ortho Diagnostic Systems Inc., Raritan, NJ). Cell viability (as determined by
trypan blue exclusion) was always >95%. In some experiments, H9, a T4' lymphocytic cell
line, was used as control. Also, in certain experiments, enriched lymphocyte populations were
obtained by elutriation followed by incubation on plastic dishes to remove adherent cells.
These cells were <2°Io nonspecific esterase positive. It should be noted that the control M/M
used in this study (i.e., elutriated cells cultured for 5 d before exposure to HIV) are different
than the M/M populations that formed the core ofour previous paper on the effect of dideoxy-
nucleosides on HIV infection in M/M (8).
Virus.
￿
A monocytotropic strain of HIV-1, HTLVIIIBa-L (kindly provided by Drs. S. Gart-
ner and M. Popovic, National Cancer Institute, Bethesda, MD), and a lymphocytotropic
strain, HTLVIIIB (Electro-Nucleonics Laboratory Inc., Silver Spring, MD), were used in
these experiments, as previously described (8) .
Drugs.
￿
AZT (Wellcome Research Laboratories, Research Triangle Park, NC), 2'3'-dideoxy-
cytidine (ddC), 2'3'-dideoxythymidine (ddT), 2'3'-dideoxyadenosine (ddA), 2'3'-dideoxyino-
sine (ddI) (Pharmacia Fine Chemicals, Piscataway, NJ), 2'3'-dideoxy-2'3'-didehydrothymidine
(D4T) (supplied by Developmental Therapeutics Program, DCT, NCI, Bethesda, MD), and
3'-azido-2'3'-dideoxyuridine (AZddU) (kind gift of Dr. R. F. Schinazi, VA Medical Center,
Decatur, GA) were diluted in distilled waterand kept at 4'C until used. The chemical struc-
tures ofAZT, AZddU, ddT, and D4T are depicted in Fig. 1. Human recombinant GM-CSF
(Sandoz Research Inst., East Hanover, NJ) was reconstituted in distilled water at 500,000
U/ml stock solution, and stored at 4'C until used. Our GM-CSF preparation contains 5.6
x 106 chronic myelogenous leukemia (CML) units per milligram of glycoprotein, as mea-0
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FIGURE 1.
￿
Chemical structure of
2'-deoxythymidine (dT) and its di-
deoxynucleoside congeners, AZT,
ddT, D4T, and AZddU. The term
2'-deoxythymidine is synonymous
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sured by minor modifications of a rapid proliferation CML assay previously published by
Griffin et al. (23).
[3H]AZT (sp act 3 Ci/mmol), and [3H]D4T (sp act 10 Ci/mmol) (Moravek Biochemical,
Brea, CA), were freeze-dried and used immediately after reconstitution.
AntiviralDrug Assay.
￿
The tests of antiviral activity were performed with minor modifica-
tions of a previously published procedure (8) . Briefly, 105 purified elutriated M/M were
seeded at day -5 in a 1-cm2 well of a 48-well plate (Costar, Cambridge, MA), and culti-
vated in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with
20% heat-inactivated FCS (Hyclone Laboratories, Logan, UT), 2 MM L-glutamine, 50 U/ml
penicillin, and 50 t~g/ml streptomycin (Gibco Laboratories) (complete medium) for 5 d in
the presence or absence of 100 U/ml of GM-CSF Unless stated otherwise, cells were treated
from day -5 with GM-CSF and then cultured in the continuous presence of this cytokine.
Cells, viruses, and FCS were tested for mycoplasma contamination, and found negative. At
day 0, M/M were preexposed for 20 min to various concentrations of drugs, and then chal-
lenged with HTLUIIIB,,-,. (80,000 cpm/ml reverse transcriptase) as previously described (8).
This is at least 10 times the minimum infective dose in 5-d cultured M/M not exposed to
GM-CSF (see Results, Fig. 2 b). Cells were kept at 37°C in a humidified atmosphere sup-
plemented with 5% C02 . 2 d after infection (day +2) cells were extensively washed in order
to remove excess virus, and cultivated under the same conditions with the same concentra-
tions ofdrugs as before. Cells were then fed every 4-5 d. In some experiments, purified lym-
phocytes stimulated at day 0 with PHA, 1 :200 vol/vol (Gibco Laboratories), or H9 T cells
were exposed to 500 viral particles/cell of HTLU-IIIB (500 times the minimum infective dose936
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for ATH8 cells, a T4 cell clone used as virus infectivity control). 20 U/ml of human rIL-2
(AmGen Biological, Thousand Oaks, CA) plus 15% vol/vol of human natural IL-2 (ABI,
Silver Spring, MD) were added to medium for lymphocytes (but not for other cells).
Viral Detection.
￿
Viral production was assessed at days 2, 5, and 7 after viral challenge,
and then every 7 d, using several different methods. (a) reverse transcriptase (RT) activity
was evaluated usinga previously described procedure (8, 24). (b) HIV-p24 antigen produc-
tion into the supernatant was assessed by a RIA and by ELISA (DuPont Co., Wilmington,
DE). (c) Syncytia formation was evaluated at regular time points by visual inspection in an
inverted microscope.
Drug toxicity was assessed in mock-infected cells cultivated for 14 d in presence of different
concentrations ofddN, by trypan blue exclusion, and by phagocytic activity using 0.8-1.t latex
beads.
Metabolism.
￿
Anabolic phosphorylation of dideoxynucleosides was analyzed using minor
modifications of previously published procedures (25, 26). Briefly, ddN metabolism was mea-
sured by incubating 5 x 106 cultivated M/M or H9 T cells, in the presence or absence of
100 U/ml of GM-CSF, in 12-well plates (Costar). After 5 d of culture, cells were exposed
to 10 uM ['H]AZT or 10 p,M [3H]D4T for 24 h in 4 ml of complete medium. Cells were
then harvested by gentle scraping, counted, pelleted afterthree washings in cold RPMI, and
immediately frozen in dry ice. Frozen cell pellets were extracted with 500 ill of60% (vol/vol)
methanol, and the methanol extracts further heated at 95°C for 1.5 min. The extracts were
clarified by centrifugation at 12,000 g for 6 min. 200-ttl aliquots were then loaded onto a
radially compressed column of Partisil SAX and eluted with an ammonium phosphate gra-
dient as previously described (24, 25). Endogenous deoxyribonucleoside-5'-triphosphate pools
and nucleoside kinases were measured as previously described (27).
Statistics.
￿
The statistical significance ofthe differenceof viral suppression by dideoxynucleo-
sides in GM-CSFstimulated cultures vs. cultures without GM-CSF was assessed using the
two-tailed student's t test.
Results
Fresh elutriated M/M cultured for 5 d before exposure to HTLVIIIBa-L were con-
sistently found to be infected in these experiments (Fig. 2). In the absence of GM-
CSF, viral production was detectable no earlier than day 7 and then increased, being
detectable at least up to day 35 (Fig. 2 A). It should be noted that the M/M popula-
tion and the culture conditions used are critical variables in experiments such as
these, since the degree of HIV infection and viral suppression by dideoxynucleo-
sides may vary substantially depending on the exact M/M population and condi-
tions (8). Culturing the elutriated M/M for 5 d before exposure to virus and drugs
is thus an important variable that should be taken into consideration.
M/M exposed continuously to 100 U/ml GM-CSF showed a high titer of viral
production (at least 10 times more than without this cytokine), consistently detect-
able by day 5. Viral production was sustained for at least 35 d. No substantial en-
hancement ofviral production was seen in most experiments using lower concentra-
tions of GM-CSF, i.e., 1 and 10 U/ml (data not shown). Since GM-CSF induces
proliferation of monocytes, we wondered whether the increase in viral production
was simply due to the GM-CSFinduced increase in cell number. However, the number
of cells 7 d after viral challenge ranged up to 20-fold higher for M/M exposed to
GM-CSF as compared with unexposed cells, whereas the increase in p24 produc-
tion at day 7 was -100-1,000-fold. (Table I and Fig. 2 A). Furthermore, in early
experiments, we tested the minimum viral dose capable of inducing consistent and
productive infection in M/M. We found that while the minimum HTLVIIIBa-L in-
fective dose for untreated M/M was 8,000 cpm/ml of RT, as little as 80 cpm/ml ofE
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FIGURE 2.
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Kinetics of HTLV
IIIBa-t, infection in M/M with
orwithoutGM/CSF 100U/ml.
(A) HIVp24 gag production
(pg/ml) in M/M exposed at
day 0 to 80,000 cpm RT/ml of
HTLVIIIB.-L and cultured in
complete medium as described.
Supernatants were harvestedfor
p24assays every 4-7 d. At each
of these time points, cellswere
washed, and fresh media was
added. (0)M/Mwithout GM-
CSF; (O)M/Mexposedto GM-
CSFfrom day -5 today28;(A)
M/MexposedtoGM-CSF from
day -5 to day0; (")M/M ex-
posed to GM-CSF from day 0
to day28. (B)HIV-p24gagpro-
duction(pg/ml) in M/Mexposed
to different multiplicity ofinfec-
tion of HTLVIIIBa-L. Open
symbols represent M/M treated
with GM-CSF from day -5 to
day 30. Closed symbols repre-
sent untreated M/M. (0/*)
M/M exposed to 80,000 cpm
RT/ml; (A/")M/M exposedto
8,000cpmRT/ml; (p/")M/M
exposed to 800 cpm RT/ml;
(O/")M/Mexposedto 80 cpm
RT/ml.
the same virus preparation induced viral infection in GM-CSFtreated M/M (Fig.
2 B). Thus, it is unlikely that the increase in cell number per se caused by GM-CSF
accounts for the major enhancement of viral production observed in our studies.
Syncytia formations were easily detected, starting from day 9, in GM-CSFM/M
exposed to HTLVIIIBa-L (Fig. 3). At this time, multinucleated giant cells were seen
in culture, in association with an inhibition of cell replication. From day 20, giant
cells became pycnotic. However, they maintained their ability to produce a large
amount of virus at least up to day 35. In one experiment, we subjected HIVexposed
GM-CSFstimulated M/M to threecycles of freezing and thawingto explorewhether
this would release additional viral particles that might be sequestered within in-
tracytoplasmic vacuoles; howeverno increase in HIV-p24 antigen wasobserved (data
not shown).
As shown in Fig. 2 a and in Table I, M/M treated with GM-CSF only before
virus challenge (that is from day -5 to day 0), followed by extensive washing to
remove this cytokine, initially gave rates of viral production comparable with those938
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TABLE I
Virus Production and Viral Suppression by AZT in Elutriated MIM Treated with GM-CSF
or Media Alone at Different Time Points and Exposed to HIV-1/HTLV-IIIea _L
105 fresh elutriated M/M were placed in culture at day - 5 in 1 ml of complete medium, and treated with
GM-CSF 1.00 U/ml from day - 5 to 28, from day - 5 to day 0, or from day 0 to 28. On day 0, M/M were
exposed to saline or AZT for 20 min and challenged with HTLV-IIIBa-1 80,000 cpm RT/ml while main-
taining AZT in the media. Viral replication was assessed by HIV-p24 antigen production in the superna-
tants. The level ofinfection is expressed in pg/ml (numbers in parentheses show the percent ofviral suppression).
Results reported here represent a typical experiment.
seen in cells continuously exposed to GM-CSF. After day 14, however, a substantial
waning in viral production was seen, and from day 35 after viral challenge this level
became similartotheviralyieldobtainedin GM-CSFunexposed M/M. Viralproduc-
tion in M/M treatedwith GM-CSF starting from day 0 was less enhanced than that
observed with continuous treatment from day -5. In some experiments, weinfected
blood-derived M/M that hadbeen allowedto mature for 5 d on plastic dishes, were
furtherpurified by adherence, and then exposed to GM-CSF. GM-CSFdid not have
anysubstantial effect onHIV replication in these 5-d adherentM/M (data notshown),
possibly because of the relatively low number of high-affinity GM-CSF receptors
in mature macrophages (28, 29). This is a topic for further research.
In similarexperiments, we exposed elutriated M/M cultivated for 5 d in the pres-
ence or absence of GM-CSF to HTLVIIIB, a lymphocytotropic viral strain (Fig.
4). In agreement with our previous experience, in the absence ofGM-CSF we ob-
tained inconsistent viral replication using this strain; productive infection was at-
tained in only three ofsix experiments using M/M not exposed to GM-CSF, and
in the productive cultures there was a delayed, lower peak ofviral production, as
compared with the results obtained using the monocytotropic strain HTLVIIIBa-l,.
However, HTLVIIIB replication in M/M exposed to GM-CSF was consistent and
easily detectable starting from 7 d after virus exposure, with a peak ofviral produc-
tion after 14-21 d ofculture -20 times greater than the maximum level obtained
without GM-CSF. We also tried to define the minimum infective dose inthesecells. As
shownin Fig. 4, weobservedthat inthe absence ofGM-CSF, at least 100 times more
Day after
infection AZT No GM-CSF
GM-CSF
(day - 5 to day 28)
GM-CSF
(day - 5 to day 0)
GM-CSF
(day 0 to day 28)
7
,am
0 70 61,703 51,100 8,000
0 .1 60 (14%) <31 (100%) <31 (100%) <31 (100%)
1 <31 (>56%) <31 (100%) <31 (100%) <31 (100%)
10 <31 (>56%) <31 (100%) <31 (100%) <31 (100%)
14 0 9,800 144,500 305,000 59,000
0.1 7,500 (23%) <31 (100%) 34 (99 .9%) <31 (100%)
1 <31 (100%) <31 (100%) <31 (100%) <31 (100%)
10 <31 (100%) <31 (100%) <31 (100%) <31 (100%)
28 0 21,000 265,400 119,100 137,100
0.1 24,500(0%) 445 (99.8%) 3,131 (97 .3%) 65 (99.9%)
1 185 (99.2%) <31 (100%) <31 (100%) <31 (100%)
10 <31 (100%) <31 (100%) <31 (100%) <31 (100%)PERNO ET AL .
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FIGURE 3 .
￿
Syncytia formation at day 14 in GM-CSF-treated M/M exposed to HIV1/HTLV
IIIsa_L . M/M were treated with GM-CSF 100 U/ml from day -5, then exposed at day 0 to
HTLVIIIBa-L 80,000 cpm RT/ml, in the presence or absence of 0.1 AM AZT or 10'iM ddT .
(A)GM-CSFtreated M/Mwithout HTLVIIIB a-L ; (B)GM-CSFtreated M/Mexposed to HTLV
IIIB a-L ; (C) GM-CSF-treated M/M exposed to HTLVIIIB.-L in the presence of 0.1 hM AZT ;
(D) Same as C, except that M/M were cultured in the presence of 10 ItM ddT .
HTLVIIIB was required to bring about a productive infection ofM/M, compared
with the dose ofHTLV IIIB required to do so in the presence ofGM-CSF Thus,
in our hands, GM-CSF induced in M/M an enhancement of HTLVIIIB replica-
tion in conjunction with a substantial reduction (at least 100-fold) of the minimum
infective dose of HTLVIIIB, an otherwise nonmonocytotropic strain of HIV-1.
Also consistent with our previous report (8), AZT induced inhibition of HTLV
IIIBa-L replication inM/M precultivated for 5 d in media alone (Table I) . Over 90%
suppression ofviral replication was obtained with 1AM AZT, and 23% suppression
was obtained with 0.1 AM . Interestingly, despite the substantial increase in HIV
production induced in such cells by GM-CSF alone, AZT was much more potent
in inhibiting viral replication in the presence of this cytokine (Fig . 5 A) ; >98% inhi-
bition of viral replication was achieved with 0.1 AM AZT, and even with 0.01 AM
AZT, N90% viral suppression was observed (this was not due to an artifact of in-
creased cell death, a point we will address later in this article) . This effect was not
seen in fresh, monocyte-depleted lymphocytes ; in these cells, 10AM AZTcompletely940
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￿
Kinetics ofHTLV-IIIB infection in M/Mexposedto GM-CSF 100 U/ml at day -5,
and challenged at day 0 with different multiplicity of infection of the lymphocytotropic strain
HTLVIIIB. Open symbolsrepresent M/Mtreatedwith GM-CSF from day -5 to day30. Closed
symbols representcontrol M/M cultivated in mediaalonefrom day -5 to day30. (0/*) M/M
exposed to 10,000 HTLV-IIIB particles/cell; (0/") M/M exposed to 1,000 HTLVIIIB parti-
cles/cell; (0/0) M/M exposed to 100 HTLVIIIB particles/cell; (O/") M/M exposed to 10
HTLVIIIB particles/cell. Shown here is a representative experiment in which some detectable
infection with HTLVIIIB was attained in M/Mnotexposedto GM-CSF While substantial viral
replication was consistently achieved in GM-CSFexposed M/M in all experiments, no detect-
able viral replication wasobtained inthree out ofsixexperimentsin M/Mnotexposed toGM-CSF.
inhibited HIV1/HTLVIIIB replication in the absence of GM-CSF, and neither
stimulation of viral production nor enhancement of antiviral activity ofAZT was
seen with exposure of lymphocytes to 100 U/ml GM-CSF (data not shown). This
is in agreement with the results obtained by Walker and Burgess (28), in which no
substantial amount of GM-CSF receptors could be detected on T lymphocytes.
To determine whether GM-CSF enhancement ofantiviral activity in M/M was
specific for AZT, or was also seen with other 2'3'-dideoxy analogues ofthymidine,
we tested the effect ofGM-CSF on three AZT congeners, ddT, D4T, and AZddU.
Although AZddU is in fact a uridine congener, it is phosphorylated by thymidine
kinase (30) and in this sense acts as congener ofAZT. We also studied three other
2'3'-dideoxynucleosides, ddC, ddA, and ddI, drugs with different bases and which
are phosphorylated in human cells by different kinases compared with AZT. The
results obtained with the monocytotropic strain HTLVIIIBa-L are shown in Fig. 5.
With each ofthe AZT congeners, there was an enhancement of antiviral activity
in the presence ofGM-CSF (Fig. 5 A). Consistent with our previous results, the
ED5o forAZT in elutriated M/M cultured for 5 d was -0.1 AM, while it decreased
down to between 0.001 and 0.01 AM when these M/M were exposed to GM-CSF.
ddT itself induced complete viral inhibition at 10 AM in elutriated M/M, the ED5o
being 1 A.M. This result is remarkable inasmuch as ddT does not have strong anti-A loo
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￿
Viralsuppression as afunction ofdrug concentration in M/M treatedwith orwithout
GM-CSF 100U/ml from day -5 andexposed to HTLVIIIB.-L80,000 cpm RT/mlin presence
of various concentrations of ddN. (O) M/M treated with GM-CSF. (") Control M/M not ex-
posed to GM-CSR (A) Percent of viral suppression in M/M exposed to four different dideoxy-
nucleoside analogues ofdeoxythymidine as noted. (B)Percent of viral suppression in M/M ex-
posed to dideoxynudeosides not relatedto deoxythymidine as noted. Viralreplication wasassessed
by HIVp24 gag production after 21 d of culture. Average control p24gagproduction (without
drugs) was as follows: M/M not treated with GM-CSF, 20,500 pg/ml; GM-CSFtreated M/M,
223,000 pg/ml. Results shown are the mean t SEM of three or more separate experiments,
except in thecase ofD4T andthelowest concentrations of ddC andddl, which were evaluated
in only two experiments. (') p<0.05; (' ') p < 0.005: (n.e.)p value notevaluated (only two ex-
periments performed).
HIV activity in T cells in our hands (7). However, in the presence ofGM-CSF, the
ED50 was lowered to 0.1 j.M. In a similar manner, the ED5o of D4T was between
0.1 and 1 uM foruntreatedM/M, andbetween 0.01 and0.1 AM for GM-CSFexposed
M/M. Finally, AZddU was only partially effective in ourhands in elutriated M/M942
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after 21 d of culture, even at the highest concentrations tested (-60% protection
at 100 AM after 21 d of culture). However, 10 pM AZddU induced complete viral
suppression in GM-CSFtreated M/M, with an ED50 of0.1-1 p.M. These data were
confirmed in two different experiments by determination of RT activity in culture
supernatants; the results were substantiallyparallel tothoseobtainedmeasuringHIV
p24 antigen production (data not shown). We also tested the ability of AZT and
its congeners to inhibit syncytia formation. As shown in Fig. 3, low concentrations
of AZT and ddT completely inhibited syncytia induced by HIV infection in GM-
CSFexposed M/M; similareffectswere seenwith D4TandAZddU (datanot shown).
We asked whether GM-CSF had an effect on viral infection and/or on antiviral
activity ofAZT in H9, a T lymphocytic cell line. Neither increase ofviral produc-
tion nor enhancement ofantiviral activity ofAZT and related congeners was seen,
in agreement with data obtained with AZT in fresh lymphocytes (data not shown).
Finally we exposed M/M to the lymphocytotropic strain HTLVIIIB in the pres-
ence orabsence ofGM-CSF. The results, shown in Fig. 6, are substantially parallel
to those obtained with the monocytotropic strain HTLVIIIB.-L, showing an overall
potentiation of viral suppression by AZT and related congeners in M/M exposed
to GM-CSF. Thus, the results indicated that AZT and each ofthe closely related
congeners tested are 10 or more times more active at suppressing replication oftwo
different strains of HIV in GM-CSFexposed M/M than in M/M not exposed to
GM-CSF.
By contrast, when we tested the effect of GM-CSF on other dideoxynucleosides
not related toAZT, we found that there appeared to besome reduction ofanti-HTLV
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FIGURE 6.
￿
Same as Fig. 5, except that the lymphocytotropic strain HTLVIIIB (1,000 viral par-
ticles/cell) wasused. Viralreplication was assessed by HIVp24gag production after21 dof cul-
ture. Control gag production (without drugs) was as follows: M/M not treated with GM-CSF,
2,150 pg/ml; GM-CSFtreated M/M, 21,600 pg/ml. Results shown here represent a typical ex-
periment.PERNO ET AL.
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IIIBa-1, activity in fresh M/M in the presence of GM-CSF (Fig. 5 B). Comparable
results were obtained using the other HIV-1 strain, HTLVIIIB (Fig. 6). Our data
do not distinguish whether this represented unchanged anti-HIV activity in the pres-
ence ofan increased efficiency ofviral replication, or alternatively, an actual reduc-
tion of anti-HIV activity. In either case, the results indicate that GM-CSF seems
to enhance the anti-HIV effect of AZT and its congeners in M/M, while the effect
ofseveral other dideoxynucleosides is unchanged or possibly even reduced in M/M
cultured with this cytokine.
To determine whether the enhanced antiviral activity ofAZT and its congeners
by GM-CSF might be due to an increased cell toxicity, we assessed this parameter
bytwodifferentmethods. Inthe absence ofGM-CSF, M/M failed to showany drug-
related toxicity, as assessed by trypan blue exclusion, at concentrations up to 100
AM AZT, 500 AM ddT, 10 AM D4T, or 100 AM AZddU (data not shown). Also,
no inhibition ofphagocytic activity wasseen atthe sameconcentrations. In the pres-
ence ofGM-CSF, phagocytosiswassubstantially unaffected bydrugs(Table II). How-
ever, high concentrations of AZT and AZddU did lower the number of M/M ex-
posed to GM-CSF in a dose-dependent fashion (Table II); in the case of AZT, a
50% reduction ofviable M/M was obtained at 10 A.M. On the other hand, 1 AM
AZT was devoid ofcytotoxicity in monocytes exposedto GM-CSF, andthisconcen-
tration is >100 times the ED5o described earlier under these conditions. Similarly,
ddT and D4T did not substantially affect cell viability at concentrations up to 500
and 10 AM, respectively. Thus, while GM-CSF does have an effect on the toxicity
ofAZT and analogues at the sametime as it increases their antiviral activity, >9570
HIV suppression by AZT analogues in GM-CSFtreated M/M is obtained at con-
centrations 10-500 times (depending on different AZT analogues) lower than those
necessary to induce such viral inhibitionin HIV-exposed T lymphocytes; moreover,
TABLE II
Toxicity of Dideoxynucleosides in M/M Exposed to GM/CSF
105 fresh elutriated M/M exposed to 100 U/ml GM-CSF were cultivated for 14 d in 2 ml of
complete medium in the presence of different concentrations ofddN . Viability was measured
by trypan blue exclusion method, and phagocytosis was evaluated after a 1-h incubation with
0.8 Et latex beads; viable cells ingesting at least two beads were considered positive.
Drug Concentration
Total
x 104/ml
viable cells
Percent of control
Phagocytic activity
(percent positive cells)
'UM
No drug - 5.2 - 92
AZT 1 6.1 >100 90
10 2.6 50 89
100 2.4 46 88
AZddU 10 5.7 >100 98
100 3.7 71 95
1,000 3.1 60 94
ddT 10 6.4 >100 95
100 5 .4 >100 93
500 6 .3 >100 96
D4T 1 6 .4 >100 96
10 4 .6 89 93944
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in the case of AZT, little or no toxicity is observed at drug concentrations typically
attained in vivo (1-3 uM).
To evaluate some possible mechanisms responsible for the interaction of GM-CSF
and AZT congeners in fresh M/M cultivated for 5 d, we studied the metabolism
of AZT and D4T in M/M with or without GM-CSF. The results are summarized
in Fig. 7 and in Table III . In the absence of GM-CSF, M/M had low levels of intra-
cellular AZT 5'-triphosphate (AZTTP). As can be seen by the high AZT5'-mono-
phosphate/AZT5'-diphosphate (AZTMP/AZTDP) ratio in Fig. 7 A, GM-CSF does
not eliminate the relative block at the level of thymidylate kinase that is character-
istic for AZT metabolism. Exposure ofthe M/M to GM-CSF dramatically increased
the intracellular levels ofboth parent AZT and its mono-, di-, and triphosphate anabo-
lites. In particular, AZTTP level increased >15-fold. These effects were not seen in
H9 T cell line exposed to GM-CSF. In part, the increase in AZTTP in M/M ex-
posed to GM-CSF may be due to an increase in the cell entry of AZT, as evidenced
by the higher intracellular levels ofAZT as parent compound. Also, GM-CSF may
have an effect on the level of intracellular thymidine kinase. The activity ofthis en-
zyme, which catalyzes the initial phosphorylation of AZT and related congeners,
and thymidine as well, is very low in M/M when compared with T cells(8, 31). M/M
exposed to GM-CSF had approximately a twofold increase in thymidine kinase com-
pared with control M/M cultured without GM-CSF (data not shown). A similar
increase in phosphorylation was obtained with D4T active metabolites ofD4T were
barely detectable in M/M unexposed to GM-CSF, whereas large amounts of both
FIGURE 7.
￿
Typical ionexchange (Partisil-10 SAX) HPLC elutionprofile of6070 methanolic ex-
tracts ofelutriated M/M (A) or H9 T cells (B)incubated for 24 h with 10 WM [3H]AZT (sp act
3 Ci/mmol) and of elutriated M/M incubated for 24 h with 10 pM [3H]-2'3'-dideoxy-2'3'-
dehydrothymidine (D4T, sp act 10 Ci/mmol) (C). Analyses were carried out using radial com-
pression columns of Partisil-10 SAXequilibrated and developed with 0.01 M ammonium phos-
phate, pH 3.6, for 15 min, followed by a linear gradient to 0.6 M ammonium phosphate, pH
3.8, over the next 25 min, andfinally by a 15 min isocratic elutionwith 0.6 M ammonium phos-
phate, pH 3.8. Sample volume: 200 pl. 1-min fractions were collected, and data are expressed
as dpm/106 cells. Note that the ordinate utilizes a logarithmic rather than a linear scale because
of the marked accumulation of AZT at the 5'-monophosphate level and the resulting disparity
in peak heights between those for AZTMP and for AZTTP. (p) Control (no GM-CSF); (O)
GM-CSF treated cells.PERNO ET AL.
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TABLE III
Intracellular Phosphorylation of AZT and D4T to Their Active Moieties; Comparisons to Levels
of Endogenous Competing dTTP Pools in M/M and H9 T Cells Exposed to GM-CSF
For phosphorylation studies, 5x 106 M/M or H9 were cultivated for 5 d in 4 ml of complete medium in the
presence or absence of GM-CSF 100 U/ml. After 5 d, cells were exposed to 10 pM [3H]AZT, or 10 'UM
[3H]D4T. After 24 h, cells were harvested (M/M after gentle scraping to detach adherent cells), counted,
pelleted, and immediately frozen. Extraction was performed as described (see text). For endogenous dTTP
pools, 2 x 107 cells were cultivated for 5 d with/without GM-CSF 100 U/ml, then harvested, counted, pellet-
ed, and immediately frozen. Endogenous dTTP pools were estimated as described (see text).
D4Tandits mono-, di-, andtriphosphatemoieties were detected inGM-CSFexposed
M/M. Indeed, thelevels in such cellswere comparable withthose seen in H9Tcells.
We also studied theendogenous 2'-deoxythymidine-5'-triphosphate (dTTP) pool,
which competes with AZTTP and related congeners at the level of viral RT. We
found that the concentration ofdTTP was very low in this population ofM/M, as
previously reported (8) for M/M tested under different conditions, and dTTP in-
creased less than twofold in M/M exposed to GM-CSF for 5-7 d (Table III). In
the currentwork, we observed that elutriated M/Mcultured for 5 d in media alone
have a very low level ofendogenous dNTPs compared with the levels obtained in
otherM/M populations (8). Thus, GM-CSFexposedM/Mhave asubstantially higher
ratio ofAZTTP/dTTP than control M/M, a result thatmight explain the increased
activity of AZT and related congeners in such cells.
Discussion
In this report, we have found that GM-CSF activates the replication of HIVI
in fresh M/M cultured for 5 d, yet at the same time it potentiates the anti-HIV
activity ofAZT and related congeners in fresh M/M. Furthermore, we show that
this effect on AZT may be accounted for by a preferential enhancement of AZT
cell entry andsubsequent phosphorylation induced byGM-CSR Similarconsidera-
tions apply to other dideoxy analogues of thymidine.
We wish to stress that any specific clinical or therapeutic inference from our data
should be made only with great caution at this time. Nevertheless, the infection of
cells belongingto the M/M lineageis increasingly recognized asanimportant event
in the pathogenesis of AIDS (2, 5, 32). M/M are currently believed to be one of
the earliest cells infected after exposure to HIV (33), and may play an important
role inspreading HIV throughout the immune system (34). In addition, monocyte-
Cell type AZT AZTMP
pmol/1
AZTDP
o6cells
AZTTP dTTP AZTTP/dTTP
M/M 1 .25 1 .40 <0.015 <0.015 1.26 <0.012
M/M + GM-CSF 11 .16 35.84 0.135 0.155 1.9 0.082
H9 1 .29 78.59 0.4 0.42 27.9 0.015
H9 + GM-CSF 1 .69 86.66 0.35 0.31 - -
D4T D4TMP D4TDP D4TTP dTTP D4TTP/dTTP
pmol/106 cells
M/M 0.08 <0.015 <0.015 <0.015 1 .26 <0.012
M/M + GM-CSF 4.42 0.45 0 .16 0.49 1 .9 0.258
H9 1.96 0.115 0 .045 0.19 27 .9 0.007946
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derived cells appear to bethe primary target forHIV infection ofthenervous system
(2, 5, 35). Thus, factors that influence the degree of replication of HIV in M/M
may influence the course ofHIV infection in patients. While certain strains ofHIV
have been reported to replicate in peripheral blood monocytes in the absence ofex-
ogenous stimulation(2, 8, 32), we show here that stimulation ofthese cells by GM-
CSF markedly enhances their capacity to permit replication ofHIV. Indeed, even
the lymphocytotropic strain of HIV1, HTLVIIIB, which in our hands does not
replicate well in unstimulated M/M, replicates quite efficiently in M/M exposed to
GM-CSF. It is conceivable that in our system, GM-CSF stimulates the production
ofhost-cell transcriptional factors that in turn can potentiate viral transcription or
posttranscriptional events (36).
It is of note that another marrow growth factor, macrophage-CSF (M-CSF or
CSF1) has been shown by Gendelman et al. (37) to enhance HIV production by
M/M. In the case ofCSFl-stimulated M/M, however, most ofthe HIV production
was reported to be sequestered in vacuoles, while with GM-CSF, abundant virus
was released into the media. Even though we failed to find evidence ofan increase
in p24 released into the media by disrupting GM-CSF-exposed M/M using three
cycles offreeze-thawing, this would not completely exclude the possibility that GM-
CSF induced a limited form ofvirus sequestration in intracytoplasmic vacuoles; to
specifically address this point, onewould have toexamine GM-CSFexposed HIV-in-
fected M/M by EM.
It is of interest that GM-CSF treatment of target M/M potently enhances the
replication ofthe lymphocytotropic strain HTLVIIIB in these cells; in this context
GM-CSF has anet effect ofconverting alymphocytotropic virus toamonocytotropic
virus (Fig. 4). Thus, the available data from this and other studies suggest that GM-
CSFis, ifanything, aneven more potent stimulus for HIV replication in M/M than
CSF1 (37, 38). GM-CSF is produced by a number ofcells in vivo (39-45). As one
such cell is the T lymphocyte (39, 42, 43), it is possible that GM-CSF might play
a central role in the progression ofHIV infection to AIDS. Antigenic stimulation
ofT cells may lead to GM-CSF production, which may then lead to enhanced HIV
replication in macrophages and, in turn, spread of virus to more T cells.
At the same time, GM-CSF markedly enhances the anti-HIV effect ofAZT and
closely related drugs in M/M. It appears to do so by substantially increasing intra-
cellular AZTTP levels, while exerting only a slight effect on the levels ofcompeting
endogenous dTTP. To some degree, the enhanced phosphorylation ofAZT may be
due to a GM-CSFinduced increase in thymidine kinase (which not only catalyzes
the initial phosphorylationofthymidine and relatedddNanalogues, butalsoisreported
to act on AZddU [30]). However, this does not appear to be the only mechanism
responsible. M/M stimulated with GM-CSF and exposed to AZT have substantially
higher levels of intracellular AZT as unphosphorylated compound than unstimu-
lated M/M, suggesting that GM-CSF may also selectively enhance the cell entry
of AZT and related drugs into M/M. It is worthwhile to point out that AZT and
its normal counterpart, 2'-deoxythymidine, very likely permeate the cell membrane
oflymphocytes and erythrocytes via different mechanisms (46); thus, lymphokines
may have differential effects on the entry of different nucleosides. Also, in the case
ofthephysiologic 2'-deoxynucleoside-5'-triphosphate, some oftheendogenous thymi-
dine pools may depend heavilyon de novo synthesis from 2'-deoxyuridine-5'-mono-PERNO ET AL.
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phosphate (dUMP), and be regulated by feedback mechanisms. The physiologic
2'-deoxynucleotide may therefore notbe affected in precisely the same way as those
arising from ddN, bychangesin membrane transport ordiffusion. Additional studies
will be required to detail the mechanism(s) responsible for the effect of GM-CSF
onthe phosphorylation ofAZT andrelatedanalogues, andthe mechanisms respon-
sible forthe reducedantiviralactivity ofddNnotrelatedtoAZTin GM-CSFexposed
M/M.
We are presently in the process ofevaluating how exposure ofM/M to GM-CSF
affects the metabolism of another dideoxypyrimidine, ddC, and a dideoxypurine,
ddA, in order to delineate the basis for the differential effects observed on antiviral
activity. Preliminary results indicate that by contrast to the >10-fold enhancement
of AZTTP induced by GM-CSF, there is only a twofold enhancement ofddCTP.
Thecompetingphysiologic nucleotide, 2'-deoxycytidine-5'-triphosphate (dCTP), how-
ever, was below thelimit ofdetection ofour assay in both ofthese cultured popula-
tions of M/M, and for this reason, we could not calculate the effect of GM-CSF
on the ddCTP/dCTP ratio. Also, while ddATP and dATP were measurable in M/M
exposed to GM-CSF, they were below the limit of detection in the media-control
(unstimulated) M/M. Thus, while these preliminary results suggestthat theincrease
in ddCTP induced by GM-CSF was substantially less than the increase ofAZTTP,
and that the increase of ddATP was likely coupled with a substantial increase in
the competing dATP, additional experiments will be needed to fully characterize
the effects of GM-CSF on the intracellular biochemistry of these dideoxynucleo-
sides. Nevertheless, we can speculate that the limited net activation ofmetabolism
ofsuch nonthymidine ddN is probably not sufficient to overcome the dramatic in-
crease in viral yield induced by GM-CSF stimulation.
GM-CSF is currently being studied as a supplementary drug for the treatment
ofAIDS because of the possibility that it may counteract the marrow suppression
inducedby HIV infection orby AZT administration. The results reportedhere sug-
gest that one may wish to closely monitor patients when usingGM-CSF in the set-
tingofHIVinfection since it might enhance viral replication. However, asalso shown
here, the simultaneous administration ofGM-CSF withAZT, D4T, or related ana-
logues mayinduce a potent antiviral effect in monocytes. Could such acombination
also increase AZT toxicity in vivo in marrow blood-forming cells? The answer is
not known; however, a recent study suggested that in contradistinction toour results
obtained in M/M, GM-CSF might reduce the phosphorylation of AZT in bone
marrow cells while increasing the levels ofthymidine triphosphate (47). It is thus
conceivable that GM-CSF may act to increase the overall therapeutic index ofAZT
andrelatedthymidine analogues. Thesimultaneous administration ofthese twoagents,
therefore, may be worth exploring in patients with severe HIV infection.
Summary
We have investigated the influence ofgranulocyte-macrophage CSF (GM-CSF)
on the replication ofHIV-1 in cells ofmonocyte/macrophage (M/M) lineage, and
itseffect on the anti-HIV activity ofseveral2'3'-dideoxynucleoside congeners ofthymi-
dine in these cells in vitro. We found that replication of both HTLVIIIBa-L (a
monocytotropic strain of HIV1) and HTLVIIIB (a lymphocytotropic strain) is
markedly enhanced in M/M, but not in lymphocytes exposed to GM-CSF in cul-948
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ture. Moreover, GM-CSF reduced the dose of HIV required to obtain productive
infection in M/M. Even in the face of this increased infection, GM-CSF also en-
hanced the net anti-HIV activity of3'-azido-2'3'-dideoxythymidine (AZT) and sev-
eral related congeners: 2'3'-dideoxythymidine (ddT), 2'3'-dideoxy-2'3'-didehydrothy-
midine (D4T), and 3'-azido-2'3'-dideoxyuridine (AZddU). Inhibition of viral
replication in GM-CSFexposed M/M was achieved with concentrations ofAZT and
related drugs, which were 10-100 times lower than those inhibitory for HIV-1 in
monocytes in the absence ofGM-CSF. Other dideoxynucleosides not related to AZT
showed unchanged or decreased anti-HIV activity in GM-CSFexposed M/M. To
investigate the possible biochemical basis for theseeffects, we evaluated the metabo-
lism of several drugs in M/M exposed to GM-CSF We observed in these cellsmarkedly
increased levels of both parent and mono-, di-, and triphosphate anabolites ofAZT
and D4T compared with M/M not exposed to GM-CSF. By contrast, only limited
increases of endogenous competing 2'-deoxynucleoside-5'-triphosphate pools were
observed after GM-CSF exposure. Thus, the ratio ofAZT5'-triphosphate/2'-deoxythy-
midine-5'-triphosphate and 2'3'-dideoxy-2'3'-didehydrothymidine-5'-triphosphate/2`-de-
oxythymidine-5'-triphosphate is several-fold higher in GM-CSFexposed M/M, and
this may account for the enhanced activity of such drugs in these cells.
Taken together, these findings suggest that GM-CSF increases HIVI replication
in M/M, while at the same time enhancing the anti-HIV activity ofAZT and related
congeners in these cells. These results may have implications in exploring new ther-
apeutic strategies in patients with severe HIV infection.
We thank Dr. S. Gartner and M. Popovic for providing the HTLVIIIBa-L strain of HIV1,
Dr. R. F. Schinazi for providing AZddU, Dr. J. M . Pluda and T. L. Gerrard for helpful
discussions, M. J . Currens for technical assistance, Y. Wilson for help in the HPLC analysis,
and P Fratantoni, L. Fowler, and C. Martin for blood donor assistance.
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